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Abstract
Recent years have brought about a marked extension of our understanding of the somatic basis of cancer. Parallel to
the large-scale investigation of diverse tumor genomes the knowledge arose that cancer pathologies are most
often not restricted to single genomic events. In contrast, a large number of different alterations in the genomes
and epigenomes come together and promote the malignant transformation. The combination of mutations, struc-
tural variations and epigenetic alterations differs between each tumor, making individual diagnosis and treatment
strategies necessary. This view is summarized in the new discipline of personalized medicine. To satisfy the ideas of
this approach each tumor needs to be fully characterized and individual diagnostic and therapeutic strategies de-
signed. Here, we will discuss the power of high-throughput sequencing technologies for genomic and epigenomic
analyses.We will provide insight into the current status and how these technologies can be transferred to routine
clinical usage.
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PERSONALIZEDMEDICINE
Recently the term ‘personalized medicine’ arose
with the goal to establish patient-specific diagnosis
and treatment strategies. Hand in hand with an enor-
mous progress in technologies, new molecularly tar-
geted agents have been developed. The combination
of both, the fast deciphering of genomic alterations
and the emergence of side-specific therapeutic
agents, paved the way for a new concept in oncol-
ogy: Treatment of tumors based on their molecular
profile nearly irrespective of their localization and
histology.
The advancement in high-throughput technolo-
gies covering DNA, RNA, proteins or metabolites
makes it possible to characterize the disease process of
an individual patient. Already first genome-wide
sequences of individual patients revealed the com-
plexity of cancer genomes: Contrary to the previous
view most tumors not only harbor one mutation, but
a multitude of different genetic and epigenetic events
which, in their combination, provide tumor-specific
patterns which need to be taken into consideration
for optimal therapeutic concepts [1–3]. Nevertheless,
in some instances tumor genomes seem to be quite
stable and depend on single tumorigenic driver
events [4]. This might be restricted to specific trans-
location-prone tumor subgroups such as chronic
myelogenous leukemia with BCR^ABL fusion
genes [5,6]. The development of targeted therapies
against the ABL kinase domain, Imatinib, resulted in
high response rates with an estimated 93% of patients
which remained free from disease progression further
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underlining the tumor’s dependency on the onco-
genic fusion gene [7].
The knowledge of the complexity of tumor gen-
omes by far surpasses our knowledge about human
biology of a few years ago. Although it took 10 years
and 1 billion dollars to complete the sequence of
the human genome just 10 years ago, we are now
able to generate that much information on one next-
generation sequencing (NGS) instrument in 10 days
(Illumina, Solid), and we expect an even further en-
hancement with whole-genome sequencing results
within less than a few days at costs of below 1000$
(e.g. PacBio announcement). This progress makes
the transfer of high-throughput sequencing (HTS)
technologies to routine clinical diagnostics likely.
First chemotherapies developed, alkylating agents
and antimetabolites, aimed on a general disruption of
cell homeostasis. Only since a few years, targeted
therapies by selective small molecule inhibitors are
in use. These drugs aim at an inhibition or activation
of specific cellular target proteins, most frequently
protein kinases. Parallel to this development the rec-
ognition emerged that only a subset of patients sig-
nificantly benefit from these chemotherapies. The
others are unsuccessfully treated, suffering from
side-effects without benefiting from the treatment.
Thus, the driving force underlying personalized ther-
apy is the enormous heterogeneity among tumors,
even among tumors of the same class. Using newest
high-throughput technologies knowledge arises that
a wide spectrum of different genetic alterations from
mutations over copy number to structural variations
are found in each tumor. This complexity is even




The worldwide personal genome project (PGP) and
the 1000 genomes project aim at sequencing thou-
sands of individual genomes to gain insight into gen-
omic variabilities [8,9]. This aim seemed to be an
illusion just a few years ago, but has now become
reality. In this direction, the development of HTS
technologies (454 (Roche), Illumina, SOLiD and
Ion Torrent (Life Technologies)) has initiated a real
revolution in genomics analyses. With these technol-
ogies, an enormous parallel analysis of genomic
DNA has become possible in a time-frame of a
few days. Key features of these technologies are the
spatial immobilization of millions of short DNA frag-
ments followed by a massively parallel sequencing
process (Figure 1). Fluorescence markers incorpo-
rated into the DNA fragments either by ligation
(SOLiD) or by polymerase activity (Illumina)
during the sequencing process, or a light signal
emitted from luciferase activity coupled to the in-
corporation of nucleotides (454FLX) are detected
by high-resolution cameras [10,11]. The Ion
Torrent technology is, even though it follows the
same process of spatial localization of DNA frag-
ments and a cycled wash mode, located between
second and third generation sequencing technolo-
gies. A semiconductor technology is used to create
micro-wells that carry out sequencing steps and sense
the incorporation of nucleotides by the release of
hydrogen ions. This eliminates the need of scanning
cameras and accelerates the sequencing process.
However, amplification and termination steps are
still required which set an upper limit for the speed
of the process.
All these sequencing technologies provide digital
information on DNA sequences which are assembled
and aligned to reference genomes using bioinfor-
matics tools. Digital information is the basis for
re-sequencing approaches as well as quantification
modules for gene expression analyses or chromatin
immunoprecipitation experiments. The parallel
sequencing of millions of DNA molecules is espe-
cially useful for sequencing heterogeneous material,
as is the case with cancer tissues.
Sequencing of entire genomes is an important ap-
plication of HTS. Although all types of genetic poly-
morphisms can be identified using whole-genome
re-sequencing approaches, this method is still too
cost-intensive to be conducted routinely. Instead,
many research and diagnostic goals might be
achieved by sequencing only a fraction of the
genome.
For many diseases, specific sets of genes involved
in the pathomechanism or implicated by whole-gen-
ome association studies are of major interest. In add-
ition, there might be limitations on sequencing
capacity to only re-sequence all protein-coding re-
gions (‘exome’) which encompass 1% of the
genome. Several targeted sequence enrichment tech-
niques to reduce DNA sequence complexities have
been established [12–16]. In particular, microarray-
based genomic selection (MGS), multiplex exon
capture or bead-based enrichment methods are
already commercially available and used for targeted












sequencing approaches. Main differences are the
amount of input DNA, the ease of performance
and if they are hybridization- or synthesis based. In
addition, as sequencing capacities per run continue to
increase and are already at throughputs of up to 3
billion reads per run, the ability to easily multiplex
multiple samples will get increasingly important.
Besides the detection of polymorphisms and mu-
tations structural variations can be detected with
HTS technologies. As such, genomic rearrangements
resulting in aberrant transcriptional events are
common features in human cancer. Thus, besides
point mutations extended genome rearrangements
are implicated in tumorigenesis such as transloca-
tions, inversions, small insertions/deletions (InDels)
and copy number variations (CNVs). InDels are
most often defined as deletions or insertions below
1 kb of DNA, whereas CNVs comprise alterations
larger than 1 kb of DNA. Recent analyses by
genome-wide approaches have uncovered the im-
portance of structural genomic variations in health
and disease. Furthermore, genetic association studies
have implicated CNVs in cancer. The connection of
changes in CNVs to several diseases has boosted the
development of new technologies to investigate
these rearrangements. First methods involve micro-
scopic examination of chromosome bandings, PCR,
fluorescence in situ hybridizations (FISH) and micro-
arrays. More recently, HTS technologies have been
utilized for these analyses. These approaches offer
important advantages over conventional methods
such as microarrays or array comparative genomic
hybridization. In particular, in addition to quantita-
tive information they provide data about qualitative
mechanisms, e.g. balanced rearrangements such as
reciprocal translocations and inversions which
would have been otherwise overseen. Moreover,
since the sequencing is based on digital modes,
they are able to detect variants that are present in a
subpopulation of cells. Given the short read-lengths
of most HTS technologies, paired-end sequencing
approaches have been developed. Here, two short
DNA segments separated by a spacer of chosen
length (typically 200 bp–2000 bp) are sequenced to-
gether. A comparison of the actual distance of the
mapped segments on the reference genome with the
chosen spacer length is able to identify insertions,
deletions and intra-/inter-chromosomal rearrange-
ments. Paired-end sequencing is in particular import-
ant for the detection of translocations and, if applied
to RNA, for the detection of splice variants.
In comparison, ‘third generation sequencing’
approaches, relying on detecting the binding of the
nucleotidetriphosphate to the polymerase in real
time (Pacific Biosciences), nanopore (e.g. Oxford
Nanopore) and scanning probe sequencing
approaches [17–19], are directed toward sequencing
of single DNA molecules without any prior ampli-
fication or labeling [20]. PacBio use optical tech-
niques to monitor single polymerases in real time:
In the procedure developed by Pacific Biosciences,
multiple ‘zero mode waveguide’ (ZMW) structures
on a chip define minute volumes containing single
polymerase molecules and restrict the area of





































Figure 1: Time line of cancer research. The first human genome was sequenced in a world-wide effort, the HGP
(Human Genome Project). The development of new technologies with high-throughput enabled, besides the fast
sequencing of individual genomes, the parallel detection of mutations, structural variations and epigenetic alter-
ations. Large-scale projects like the TCGA (The Cancer Genome Atlas) and the ICGC (International Cancer
Genome Consortium) aim at sequencing more than 500 cases for each cancer entity.












detecting fluorescence signals to the bottom 30 nm
of the ZMW. DNA sequences are read out by the
series of desoxynuclotidetriphosphates that are
labeled with different fluorescent dyes and illuminate
during the incorporation step. Key to the detection
process is that the incorporation process takes milli-
seconds, which is approximately three orders of mag-
nitude longer than simple diffusion. This difference
results in a higher signal intensity for incorporated
versus unincorporated nucleotides. During incorpor-
ation of the triphosphate analog, the fluorescent label
is cleaved off together with the pyrophosphate
group, allowing the next incorporation step. Thus,
the combination of the ZMW technology with the
immediate release of the fluorescent dye during the
incorporation enables a real-time sequencing detec-
tion. In addition to determining the sequence, this
procedure has been shown to also be able to detect
base modifications in the DNA, due to their influ-
ence on the kinetics of incorporation [21]. The basic
principle of nanopore sequencing is such that a DNA
strand or a cleaved nucleotide is passed through a
nanopore and induces changes in the current applied
[17]. The use of electrical currents for nucleotide
identification promises the discrimination of all four
nucleotides and, in addition, the identification of
methylated cytosines. That would implicate that
during one sequencing process all ‘five’ nucleotides
(A, T, C, G and 5mC) could be distinguished (in
addition to further nucleotide modifications) and no
additional manipulation of DNA would be required
for the construction of DNA methylation patterns.
In another approach under development, called
scanning probe sequencing, the DNA molecule is
immobilized and the scanning instrument records
the nucleotides [19].
TUMORGENOMES
The nucleotide sequence is the primary level of gen-
etic information and the basic principle of genetic
inheritance. A first connection between alterations
in the genome and cancer was discovered in 1960
by Nowell and Hungerford who found a consistent
chromosomal abnormality in leukemic cells
(Figure 2) [5]. This abnormality was later called
‘Philadelphia’ chromosome, a translocation between
the long arm of chromosome 9 and 22, leading to
the oncogenic activation of ABL (‘Abelson Murine
Leukemia Viral Oncogene Homolog 1’) [22].
Further studies revealed copy number alterations
(gain and loss) and mutations in single genes leading
to an activation of oncogenes or inactivation of
tumor suppressor genes. Prototype oncogenes are
MYC (v-myc myelocytomatosis viral oncogene
homolog) and the tumor suppressor gene RB1 (ret-
inoblastoma 1). For a long time such genomic events
were thought to be single events sufficient for the
tumor progress. However, through large-scale
sequencing studies it turned out that this is by far
not the case and that a multitude of genomic alter-
ations mark cancer genomes. The combination of
these events make up a complex pattern underlying
each individual cancer genome and the sum of these
events may drive tumorigenesis. Thus, the under-
standing of oncogenic processes has turned from
single-gene alterations to pathways which are fre-
quently disrupted. This view fits very well to the
notion that no single gene has been identified
which is altered in all patients. As a consequence of
this changed view it becomes difficult to identify
genomic biomarkers with high specificity and sensi-
tivity. Nevertheless, genomic information may be
used for personalized medicine approaches where
each cancer patient is treated with drugs tailored
for his particular tumor. But even here, due to the
broad array of different mutations found in each
cancer, it becomes difficult to find clinical trials
where special patients might be integrated. Either
we need new forms of clinical trials in terms of per-
sonalized medicine studies or we need a broader
array of drug testing studies [23].
TUMOR EPIGENOMES
Besides genomic information, another level of tumor
complexity arises from epigenetic variations of DNA
segments which are also underlying the inheritance
of phenotypes from generation to generation as well
as from cell to cell during cell division [24].
Genome-wide studies on epigenetic changes are
now termed ‘epigenomics’. Epigenetic variations
can be grouped into covalent DNA modifications,
in particular methylation of nucleotides, or post-
transcriptional modifications of histones (e.g. acetyl-
ation, ubiquitinylation or methylation) and—on a
higher order—chromatin remodeling processes.
Here, chromatin remodeling means the dynamic
compaction of the genome including the activity
of ATP-dependent chromatin remodeling com-
plexes and non-coding RNAs. Less compacted
structures can be visualized as light-colored bands












when stained and observed under an optical micro-
scope, whereas heterochromatin, tightly packed
chromatin, stains darkly and is mainly associated
with transcription-silent regions.
Epigenetic modifications play critical roles in all
DNA-based processes including transcription, DNA
repair and replication [25]. The development of
HTS technologies has dramatically advanced our
view of genome-wide epigenetic events. With this
it became possible to provide comprehensive maps of
nucleosome positioning and chromatin conform-
ation [26,27]. In addition, transcription factor bind-
ing sites as well as post-transcriptional modifications
of histones are localized with chromatin immuno-
precipitation techniques followed by HTSs (ChIP-
Seq) [28,29]. Here, antibodies against the protein or
modification of interest are used to pull out the anti-
gen/protein from cellular extracts. Through preced-
ing cross-linking approaches proteins which have
been pulled out carry their bound DNA as ‘back-
pack’ with them. HTS then provides specific site
information where the protein of interest or the his-
tone with the modification of interest binds. A pre-
requisite for this technology are antibodies with high
specificities and high overall qualities. At the
moment these antibodies are main limitations for
high-throughput analyses and careful quality controls
need to be performed for each antibody.
In humans, cytosine methylation was the first
mark discovered. In the current paradigm it is
required for the regulation of gene expression as
well as for silencing transposons and other repetitive
sequences [30]. The chemical modification occurs
predominantly via a covalent attachment of a
methyl group to the C5 position of the cytosine
ring (5mC) in CpG dinucleotides. Thereby, the
structure of cytosine is altered without changing its
base-pairing properties. Altered DNA methylation
patterns have been reported in a diverse array of
complex human diseases such as cancer, systemic
autoimmune and psychiatric diseases as well as in
monogenic epigenetic diseases [31]. In this regard,
the first molecular epigenetic change, a global reduc-
tion of DNA methylation in cancer cells, has been
described by Feinberg and Vogelstein [32] and in the
same year by Gama-Sosa et al. [33]. These changes
Figure 2: Schematics of the sequencing process. (A) Modern Sanger sequencing is based on the labeling of nucleo-
tides with different fluorescence dyes and a termination chemistry. Size separation of the fragments resolves the
sequence. (B) NGS technologies provide sequence information on millions of DNA fragments in parallel. The reso-
lution of single fragments is achieved by an immobilization of the DNA fragmentsças here illustrated by the
Illumina processçand the scanning of fluorescence intensities after each nucleotide incorporation cycle. New nu-
cleotides are incorporated stepwise after periodic scan-and-wash cycles.












were found in both preinvasive and invasive cancers
and implicate that alteration in the cytosine methy-
lation patterns are among the earliest events in
tumorigenesis. In addition, it has been shown that
specific alterations in the cytosine methylation pat-
terns of CpGs in promoter regions are associated
with certain tumor entities or stages. Overall, the
extend of epigenetic modifications in cancer tissues
is extraordinary different from their normal counter-
parts (Figure 3). For DNA methylation more than
150 000 significantly differentially methylated re-
gions can be identified [34]. This is, in particular,
interesting for the identification of biomarkers, be-
cause it is more likely to identify reliable markers for
any given clinical question when they can be selected
out of a large set of alterations than if they are based
on single and often infrequent events such as muta-
tions. Consequently, the first biomarkers have been
developed on the basis of these modifications [35].
Third generation sequencing instruments contain
the promise to directly identify modified nucleotides.
Otherwise, modified nucleotides need to be either
enriched by, e.g. chromatin immunoprecipitations,
or chemically treated to distinguish them from the
‘background’. Over the past years, several epigenetic
technologies have been developed either for profil-
ing methylated genomic regions (indirect methods)
or for typing the methylated base (direct methods).
These approaches differ concerning the obtainable
resolution with direct methods resulting in single-
nucleotide patterns of methylated cytosines within
genomes, whereas indirect methods measure average
methylation levels across many molecules [36–39].
Using HTS technologies for the interrogation of
DNA methylation patterns, the classification into in-
direct and direct approaches can be maintained and
extended: Indirect methods include affinity-enrich-
ment sequencing (AE-Seq: MeDIP-Seq and MBP-
Seq) methods and methods that use endonuclease
digests followed by sequencing (Enzyme-Seq:
Methyl-Seq, MCA-Seq, HELP-Seq, MSCC) [24].
Methylation profiles are then inferred by subsequent
sequencing, read alignment and counting of reads
per genomic interval. Direct methods—BS-Seq,
BC-Seq, BSPP and RRBS—in contrast rely on
bisulfite conversion of unmethylated cytosines and
consecutive sequencing, which allows methylation
profiling with a resolution on single base level.
Indirect approaches provide information as a
methylation score for regions of 100–200 bp
length. All methods are based on the enrichment
of methylated DNA. The fragments captured by
any of those methods can then be identified by either
hybridization to known sequences or by sequencing.
The use of HTS instead of custom-designed hybrid-
ization-arrays to identify precipitated DNA frag-
ments provides genome-wide information about
methylated regions. This implies that all DNA frag-
ments can be identified and not only pre-selected
regions which are immobilized on an array. The
completeness of the data is especially advantageous
in generating methylation profiles outside of CpG-
islands and promoter regions, for example in gene
bodies where DNA methylation changes have
recently been shown to occur [40,41].
MeDIP-Seq (methylation-dependent immuno-
precipitation) and MBP-Seq (methyl-binding
protein) rely on precipitations of DNA fragments
containing methylated cytosines (5mC) and use an
anti-5mC antibody or methyl-binding proteins
(MBPs) [42–45]. Both methods belong to the class
of affinity-enrichment sequencing approaches
(AE-Seq).
The MeDIP-enrichment depends upon the 5mC
content in a way that a threshold level of methyla-
tion, 2–3%, is required for a successful enrichment
[34]. Regions with high CpG content are, therefore,
more likely to be enriched than regions with low
CpG content. First MeDIP-seq experiments indicate
that 30–40 million reads are required for a human
genome-wide analysis [36,46]. MeDIP-seq
approaches have been performed so far using
Illumina’s Genome Analyzer technology [46] but
we recently established several methylation analysis
methods for SOLiD sequencers, because of im-
proved throughput [34]. MBPs preferentially bind
double-stranded DNA with symmetrically methy-
lated CpG sequences and, in contrast to MeDIP-
protocols where the DNA is denatured and single
stranded, the adapter ligation step is less critical and
can be performed after the affinity purification. A
challenge of both AE-Seq methods is that ‘no
signal’ can be explained either by very low methy-
lation levels or experimental failure and hypomethy-
lation patterns are, therefore, very difficult to assess.
Protocols that use endonucleases (Enzyme-Seq
technologies) like Methyl-Seq [47], MCA-Seq
[48], HELP-Seq [49] and MSCC [41,50] exploit
the fact, that restriction enzymes exists which target
sequences that comprise CpG sites in a methylation
sensitive manner. Following DNA digestion all
Enzyme-Seq methods encompass a size selection












step to ensure that the fragments selected for sequen-
cing are close to the CpG site [47]. Analysis is done
by counting the reads per genomic region and com-
bined evaluation of treatment and control samples. If
no control samples exist methylation-sensitive (e.g.
HpaII, SmaI) and methylation-insensitive (e.g. MspI,
XMaI) preparations can be compared, a step which is
also advisable if copy number variants are expected
to be present [49]. A drawback of the Enzyme-Seq
methods is that any region showing at least one read
in the methylation-sensitive digest is currently called
‘unmethylated’. Thereby the quantitative methyla-
tion state of the individual region is lost, and partial
methylation remains unidentified [41,47].
Direct assessment techniques like BS-Seq [51–53],
BC-Seq [54], BSPP [41,50,55,56] or RRBS [57,58]
determine methylation profiles directly from the se-
quence enabling base pair resolution. Methylated
DNA is marked through a ‘bisulfite (BS) conversion’
reaction for which genomic DNA is treated with
Figure 3: Circos plot for the distribution of differentially methylated regions in cancer. All chromosomes are
arranged in a circle (middle). The inner circle shows the number of significantly differentially methylated regions.
Peak heights and color represents the number of alterationsçwith dark high peaks indicating a high number of dif-
ferential methylation.The outer circle indicates locations of oncogenes and tumor suppressor genes.












sodium bisulfite under denaturing conditions.
Cytosine residues get deaminated and converted to
uracil leaving methylated cytosine moieties un-
affected [59]. Identification of the resulting DNA
sequence leads to a detection of converted and un-
converted cytosine residues and subsequent identifi-
cation of the prior methylation status of the
nucleotide. The analysis deduces that cytosine resi-
dues within a CpG context were methylated if they
have not been converted by bisulfite. Common to all
direct investigation techniques are pitfalls leading to
false positive methylation calls due to incomplete
conversion reactions, degraded DNA caused by
harsh conversion conditions and methylation in
pseudogenes [60,61]. With the aid of HTS technol-
ogies do whole human genome m5C patterns
become feasible [62]. Major challenges for whole-
genome BS sequencing are the sequencing capacities
and costs required, which are still relatively high.
Thus, it is more practical to investigate only parts
of the genome if one wants to gain insight into
methylation patterns of mammals, especially if large
numbers of samples need to be analysed.
DNA methylation analysis methods cannot easily
be compared as many approaches have competing
strengths and weaknesses. The number of samples,
which can be analysed in parallel, the quantity of
DNA and the desired resolution are the central de-
cision points.
Taken together, the number of different HTS
technologies is large, and each has its own advantages
and disadvantages. The selection of the right tech-
nology for the research question investigated is cru-
cial in making the most out of the enormous power
HTS has for basic and clinical directions of research.
CLINICALAPPLICATIONSOF
HIGH-THROUGHPUTDATA
A number of tumor biomarkers have been developed
based on aberrant genomic and epigenomic (in par-
ticular DNA methylation) profiles and are used as
diagnostic, predictive and prognostic tools. As pre-
dictive biomarkers they enable the stratification of
patients in subgroups which should either receive a
specific treatment or not [63,64]. Well-established
examples include the sequencing of KRAS before
Cetuximab treatment or the determination of the
estrogen receptor status for Tamoxifen [63]. Only
colorectal cancer patients with wild-type KRAS
benefit from Cetuximab, an antibody directed
against EGFR. Tamoxifen is an antagonist of the
estrogen receptor, thus only hormone receptor-posi-
tive breast cancer patients will respond to the antag-
onist. An example for an epigenetic biomarker,
hypermethylation of MLH1, a protein of the DNA
mismatch repair, predicts sensitivity to cisplatin in
colorectal cancer [64]. There are many more ex-
amples available for specific biomarkers either already
in clinical use or in clinical testing. However, one
commonality is that they are used in a hypothesis-
driven manner: Patients with colorectal cancer are
exclusively screened for KRAS mutations; or breast
cancer patients are examined for the expression of
the estrogen receptor. For these biomarker—dir-
ected decisions HTSs are not required. In contrast
to these specific analyses new concepts of persona-
lized oncology are emerging: Here the treatment of
tumors is directed by their genome-wide molecular
profile. This means that whole genome, whole
exome and transcriptome profiles of a tumor patient
will be generated within days. Afterwards a tumor
board consisting of oncologists, radiologists, molecu-
lar geneticists and pathologists, and other related dis-
ciplines, will then determine the appropriate
treatment of the patient based on his genetic infor-
mation [65]. First proof-of-concept studies illus-
trate the effectiveness of this approach [23,66].
However, much more experience need to be
acquired before a conclusion can be drawn. At the
moment different strategies are explored how to
streamline the analysis process and how quality con-
trols can be set up. The transfer of the large amount
of data into clinical usable information is far from
easy and routinely preformed. We are right now at
the boarder to clinical applications of HTS and it will
be a question of time until large-scale genomic and
epigenomic technologies are used as routine tools for
the finding of diagnoses and for making therapy
decisions.
Although data generation has increased exponen-
tially, we are faced with new challenges to transform
these data into useful models that help predicting the
outcome of genomic aberrations (e.g. in the cancer
field) and to develop novel diagnostic and thera-
peutic strategies. The challenges are enormous and
require completely new types of infrastructure, for
example data storage that dynamically adapts to data
volumes not seen before. International quality and
data format standardization are essential to compare
data and utilize them in different modeling
approaches. Another challenge will be to translate












the gained knowledge and models into day-to-day
medical applications to finally benefit the patient
with a personalized systems medicine. Systems biol-
ogy technologies and modeling will contribute on
the level of disease target detection, diagnostic and
therapeutic approaches.
FUTURE PERSPECTIVES
The complexity of individual genomes is too large to
be comprehended just by looking at the list of
changes. There are two possibilities how to treat
this large amount of data: Either by extraction of a
subset of data, e.g. by looking at all drug targets and
known biomarkers (following a conventional way of
data analysis), or by application of computational
modeling approaches. Different kinds of mathemat-
ical and computational modeling approaches exist
[67]. Spatial models take the spatial organization of
individual cells into account. Non-spatial stochastic
models are adapted to specific purposes such as the
role of chromosomal instabilities in tumor initiation
or the role of Wnt signaling. Compartmental models
investigate the transformation of cell types without
taking their position within the colonic crypt into
account.
Difficulties exist with the comparability of the
models in regard to their functions included, e.g.
investigation of cell differentiation, growth, turn-
over, etc. Even more difficult is their evaluation in
regard to their capability of describing biological pro-
cesses. Not only qualitative measurements, but also
quantitative ratings would be desirable in order to
improve the models and to assess their ability to pre-
dict disease stages or therapeutic strategies. First
attempt are undertaken to integrate different sub-
cellular levels (genomic, proteomic) combined with
cellular (cell–cell communication) and tissue (move-
ment and migration) levels within a unifying model.
It is also desirable to add kinetic information. One
way may be to integrate missing parameters, which
are sampled from appropriate random distributions,
e.g. by applying a Monte Carlo approach [68].
Further work on these models will refine relation-
ships and will give predictive output with an im-
proved degree of certainty. Difficulties arise
because valid and rapid in vivo test systems for the
output information are missing. In oncology it is
important that an optimal treatment can be assigned
without delay and that it is adapted to the individ-
ual’s specific properties. Thus, even though the
computational modeling approaches are just begin-
ning to emerge, the hope is that the computer
models will help with in silico predictions to optimize
treatment strategies, which might further on have a
significant impact on the outcome of the disease.
Key Points
 Most often tumor patients are treated regardless of alterations
within their genomes and epigenomes leading to a large number
of patients treatedwithout benefit.
 Recent progress in HTS technologies has paved theway for per-
sonalized medicine: Tumors are sequenced and depending on
their mutations, structural variations and epigenetic modifica-
tion individual drug combinations are proposed. First clinical
studies encompassing this concept are under way.
 The development of HTS technologies has initiated a large
number of different applications with several pros and cons.
Some of them are on the border to routine clinical usage;
others are destined for basic research. Knowledge of the differ-
ent technologies is key for understanding the concept of perso-
nalizedmedicine.
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